公开(公告)号：US20210122821A1

公开(公告)日：2021-04-29

申请号：US17128241

申请日：2020-12-21

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CAROLINE DENIS ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00

Abstract: This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizaing agents and PD-1 neutralizing agents for the treatment of cancer.

公开(公告)号：US20200332008A1

公开(公告)日：2020-10-22

申请号：US16924288

申请日：2020-07-09

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US20200299383A1

公开(公告)日：2020-09-24

申请号：US16894937

申请日：2020-06-08

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20150132316A1

公开(公告)日：2015-05-14

申请号：US14594322

申请日：2015-01-12

Applicant: INNATE PHARMA, S.A. ,  UNIVERSITY OF GENOVA

Inventor： ALESSANDRO MORETTA ,  EMANUELA MARCENARO ,  FRANCOIS ROMAGNE ,  PASCALE ANDRE

IPC: C07K16/28 ,  G01N33/569

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/572 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/76 ,  G01N33/56966 ,  G01N2333/70596 ,  G01N2500/04

Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.